Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Efforts are underway to modernize clinical trial standards and normalize regulations to facilitate international collaboration. But as the European Union's Clinical Trials Directive shows, a one-size-fits-all regulatory strategy may be easier to conceive than to implement.
A drug commonly used to treat high blood pressure shows promise as a treatment in mouse models of Marfan syndrome and muscular dystrophy (pages 204–210).
A new approach to treating leaky blood vessels emerges from a proteomic analysis. The findings have implications for diabetic retinopathy and other diseases associated with increased vascular permeability (pages 181–188).
The ability to visualize brain pathology in living individuals with Alzheimer disease could change how the disease is diagnosed and drugs to treat it tested. A recently developed positron emission tomography tracer helps to image fibrillar amyloid-β and neurofibrillary tangles and brings us closer to this goal.
An inhibitor of the Wnt signaling pathway mediates bone destruction in inflammatory arthritis. The inhibitor may be the key to understanding why in some joint diseases bone is destroyed and in others built up (pages 156–163).
With a dash of tech savvy and a dose of medical wisdom, Vikram Kumar is trying to solve intractable problems in public health—and all at the ripe old age of 30.
Far from the unhurried killer it seemed to be, HIV is a swift assassin,gutting the body's immune system within days of infection. Erika Check finds out how this new paradigm is transforming AIDS research.